Platanoside Suppresses Ferroptosis in Acute Lung Injury via Keap1/Nrf2/GPX4 Axis

Study Background and Research Question

Acute lung injury (ALI) remains a critical condition in intensive care, with mortality rates as high as 30–40% due to persistent inflammation and oxidative stress disrupting alveolar–capillary integrity. Conventional therapies, including corticosteroids and antioxidants, have shown limited clinical benefit, often due to their restricted focus on single pathways and lack of tissue specificity. Emerging strategies targeting cell death pathways—particularly ferroptosis, a regulated form of necrosis driven by iron-dependent lipid peroxidation—are gaining attention. The nuclear factor erythroid 2-related factor 2 (Nrf2)–glutathione peroxidase 4 (GPX4) axis is central to cellular antioxidant defense and ferroptosis inhibition, yet its pharmacological activation in ALI remains underexplored. The central research question addressed by the recent study (Chen et al., 2026) is whether platanoside, a flavonoid glycoside, can prevent ferroptosis and mitigate ALI by modulating the Keap1/Nrf2/GPX4 pathway through autophagy-mediated mechanisms.

Key Innovation from the Reference Study

The main innovation of the study lies in demonstrating that platanoside (PLA) directly interacts with Keap1 to promote its autophagic degradation, thereby releasing Nrf2 from suppression and enhancing GPX4 expression. This represents a distinct mechanism from traditional Nrf2 activators, which typically act upstream or by oxidative modification, and instead leverages the cell’s autophagy machinery. By facilitating p62/SQSTM1-dependent Keap1 degradation, PLA effectively establishes a self-amplifying circuit for antioxidant response activation. This mechanistic insight not only elucidates a new pharmacological action for PLA but also offers a blueprint for designing interventions that target multiple arms of redox and cell death regulation in ALI (Chen et al., 2026).

Methods and Experimental Design Insights

The authors employed a combination of in vivo and in vitro models to dissect the effect of PLA on ferroptosis in ALI. Mice were subjected to lipopolysaccharide (LPS)-induced ALI, a well-established inflammatory injury model that reliably recapitulates key features of human disease. PLA was administered prior to and after LPS challenge to assess both prophylactic and therapeutic effects. Major experimental endpoints included measurements of pulmonary Keap1, Nrf2, and GPX4 protein levels, markers of lipid peroxidation (malondialdehyde, 4-hydroxynonenal), and histopathological evaluation of lung tissue. The latter was likely supported by established stains such as Hematoxylin and Eosin, which remain the gold standard for tissue morphology visualization in lung injury models. Mechanistic studies further utilized immunoprecipitation to confirm PLA-induced Keap1–p62 complex formation and monitored autophagic flux by assessing LC3 and p62 dynamics. The direct interaction between PLA and Keap1 was substantiated through biochemical binding assays.

Protocol Parameters

• ALI Induction: LPS administered via intratracheal or intraperitoneal injection (dosage and timing per standard ALI protocols).
• PLA Administration: Dosing regimen optimized for bioavailability and pharmacodynamic coverage; administered pre- and post-LPS challenge to evaluate preventive and therapeutic efficacy.
• Histological Assessment: Lung tissues processed using paraffin embedding or frozen sectioning, followed by Hematoxylin and Eosin staining for evaluation of alveolar structure, inflammatory infiltration, and tissue integrity.
• Ferroptosis Markers: Quantification of 4-hydroxynonenal and malondialdehyde via immunohistochemistry or biochemical assays.
• Protein Expression Studies: Immunoblotting and immunofluorescence for Keap1, Nrf2 (including nuclear translocation), GPX4, LC3, and p62.
• Protein Interaction Studies: Co-immunoprecipitation to confirm Keap1–p62 complex formation upon PLA treatment.

Core Findings and Why They Matter

Key results from Chen et al. (2026) demonstrate that PLA administration in LPS-induced ALI mice significantly reduced pulmonary Keap1 levels and promoted Nrf2 nuclear translocation. This led to marked upregulation of GPX4, the critical enzyme for detoxifying lipid peroxides and blocking ferroptosis. PLA-treated animals exhibited lower levels of lipid peroxidation products, attenuated mitochondrial damage, reduced inflammatory cell infiltration, and overall improvement in lung histopathology. Mechanistically, PLA enhanced Keap1–p62 complex formation, facilitating autophagy-mediated Keap1 degradation. These findings collectively establish that targeting the Keap1/Nrf2/GPX4 axis via autophagic mechanisms can robustly suppress ferroptosis and tissue damage in ALI. This approach stands in contrast to earlier therapeutics that addressed only single-pathway modulation, and instead harnesses a multifaceted regulatory network to preserve cellular integrity during acute inflammation.

Comparison with Existing Internal Articles

Several internal resources, including "Platanoside Mitigates Ferroptosis in Acute Lung Injury via Keap1/Nrf2 Axis" and "Platanoside Mitigates Ferroptosis in Acute Lung Injury via Keap1/Nrf2/GPX4 Axis", have summarized the foundational mechanisms by which PLA exerts its protective effects in ALI. These articles highlight the importance of autophagy-mediated Keap1 degradation and subsequent Nrf2/GPX4 pathway activation. The current reference paper builds upon these summaries with deeper mechanistic evidence, including direct PLA–Keap1 interaction assays and comprehensive in vivo efficacy data. Additionally, previous internal coverage of Hematoxylin and Eosin (H&E) staining methods—such as "Hematoxylin and Eosin (H&E) Staining Kit: Reliable Solution"—emphasizes the importance of robust tissue morphology visualization in evaluating lung injury and repair. The integration of advanced H&E staining kits supports the reproducibility and clarity of histopathological assessment in studies like the PLA–ALI investigation, where cellular structure assessment is central to outcome evaluation.

Limitations and Transferability

While the study provides compelling preclinical evidence for PLA’s efficacy in ALI, several limitations should be considered. The research is currently restricted to animal models and in vitro assays; translational relevance to human ALI requires further validation. The specific pharmacokinetics, optimal dosing, and safety profile of PLA in larger mammals or clinical settings remain to be established. Moreover, while the Keap1/Nrf2/GPX4 axis is broadly conserved, there may be disease- and species-specific factors affecting pathway responsiveness. The study’s focus on acute inflammation and ferroptosis in ALI does not directly address other forms of cell death or chronic lung pathology, which may involve additional regulatory networks. As highlighted in the internal articles, the broader application of such autophagy-modulating interventions in other oxidative stress-related diseases is promising but awaits direct experimental confirmation.

Research Support Resources

For laboratories seeking to replicate or extend findings in acute lung injury models, robust visualization of tissue morphology is essential. The Hematoxylin and Eosin Staining Kit (SKU K1142) offers a ready-to-use solution for histopathological tissue staining, supporting both paraffin and frozen section workflows. Accurate nuclear and cytoplasmic contrast, as achieved by nuclear staining with hematoxylin and cytoplasmic staining with eosin, is critical for assessing the structural consequences of ALI and the efficacy of interventions like platanoside. Researchers can reference the product information for practical guidance on protocol integration and storage. This kit is intended for scientific research use and aligns with best practices in cellular structure assessment for disease model studies.